SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs has traders focused on BRIUMVIs sales momentum and whether the Q3 report confirms continued growth, with subcutaneous BRIUMVI data also drawing attention. Buyout and short-squeeze theories are adding to the excitement, but remain speculative; some traders view the move as positioning ahead of earnings instead.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results are driving discussion: despite beating estimates and slightly raising its outlook, the shares have sold off sharply. Traders debate whether the results show real progress or mask weak underlying momentum, while bulls point to the cash balance and buyback and bears focus on execution and competitive risks.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generacs quarterly report has refocused attention on its data-center power business, with traders highlighting a larger backlog and the Amazon supply agreement as growth drivers. The reaction is divided: bullish traders see a longer-term AI-infrastructure opportunity, while others point to softer sales, unchanged full-year guidance, lower margins in the faster-growing C&I business, and profit-taking.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp selloff and a break below key support, with traders linking pressure to expectations of higher rates as inflation and oil prices remain elevated. The community is also debating whether forced liquidations and selling alongside risk assets explain golds failure to act as a safe haven, while some investors view the decline as a buying opportunity.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

CEO Jason Fews Bloomberg interview has drawn criticism for offering little detail on the manufacturing ramp and the delayed Texas data-center agreement, intensifying concerns about management transparency and execution. Some traders remain bullish on fuel-cell demand from AI data centers, while others point to the delays, steep share-price decline and high short interest as reasons for caution.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened amid inflation and interest-rate concerns, with traders pointing to higher expected rates and yields as headwinds for the non-yielding metal and gold miners. The community is split between expecting further technical downside and viewing the selloff as a buying opportunity, while some note miners can amplify moves in gold.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a digital-asset treasury tied to Hyperliquids HYPE token, with traders debating why the shares have lagged HYPEs gains. Bulls point to potential catch-up momentum, while skeptics cite dilution from the equity financing facility and valuation relative to the companys token holdings as possible headwinds.

Realty Income Corp. is a real estate company, which engages in generating dependable monthly cash dividends from a consistent and predictable level of cash flow from operations. The company was founded by William E. Clark, Jr. and Evelyn Joan Clark in 1969 and is headquartered in San Diego, CA.

Realty Income Corp.

Rising Treasury yields and expectations of higher interest rates are weighing on Realty Income and REITs, as investors compare its income stream with government bonds. Traders are split between buying the dip for the elevated monthly dividend and warning that rate pressure could drive further declines.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Anticipation of Compass Pathways completing its rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, is the dominant topic, with traders focused on a potentially accelerated FDA review and eventual approval. Many remain bullish on the regulatory and commercial opportunity, while others are frustrated by the filing delay and caution that approval is not assured amid weak biotech sentiment.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention for a sharp rebound and renewed buying momentum, with traders watching whether it can clear resistance and sustain a breakout. Bulls are accumulating and pointing to Chainlinks role in institutional tokenization and interoperability, while skeptics warn that the rally could fade and question whether network adoption translates into value for the token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement 

Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’

Equity

Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks

The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.

Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT

Investing.com-- Eli Lilly and Company (NYSE:LLY) is in advanced talks to buy gene editing start-up  Verve Therapeutics  Inc (NASDAQ:VERV), the Financial Times reported on Monday, as the world’s biggest drugmaker seeks to increase its pipeline of experimental drugs. 

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Verve Therapeutics Inc

Neutral Sentiment

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments">announced</a> its intent to acquire the company for up to $1.3 billion.Verve is developing gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD), such as low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a), through treatments that may only need to be given once in a lifetime.Under the terms of the deal, Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones. The aggregate value of the deal is approximately $1.3 billion.The upfront purchase price of $10.50 represents a premium of over 67% to Verve’s closing price on Monday.The transaction is expected to close in the third quarter, subject to customary closing conditions.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VERV">VERV</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1262/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_18_59_AM_png_4e0f45260c.webp" alt="VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1262" height="134"><figcaption>VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the offer seems low.<stembedurl>https://stocktwits.com/XavierXV/message/618132279</stembedurl>Another user believes that the offer is ‘terrible’ for long-term shareholders while being great news for those who bought it recently.<stembedurl>https://stocktwits.com/PensionPulse/message/618129981</stembedurl> Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> stayed unchanged within ‘neutral’ territory, coupled with ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:1268/142;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_21_01_AM_png_80a8da75d9.webp" alt="LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1268" height="142"><figcaption>LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure>Both LLY and VERV stocks are up by about 4% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-expects-tesla-deliveries-to-dip-further-in-2025/chlYvypRRTv">Wells Fargo Expects Tesla Deliveries To Dip Further In 2025, But Retail Says Downward Trend Is Over</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Verve Therapeutics Stock Rockets 76% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B

Lilly(Eli) & Co

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERV Verve Therapeutics Inc

Latest VERV News